Supplementary Tables
Table S1: Institutional ethics committees that approved the study
S.No Ethics committees Numbers
1 Ethics Committee of The First Affiliated Hospital, College of Medicine, Zhejiang University 2016 Lun Shen No. (80)
2 Ethics Committee of Beijing Huairou Hospital NA
3 Ethics Committee of Zaozhuang Municipal Hospital ZZSLEC-2017-003-01
4 Ethics Committee of Beijing Anzhen Hospital NA
5 Ethics Committee of The Second Hospital of Tianjin Medical University Interim (2017) No. (003) 6 Ethics Committee of The Affiliated Hospital of Shandong University of Traditional Chinese Medicine AF/SC-08/02.0
7 Ethics Committee of Weihai Central Hospital IEC-AF/17-1.0
8 Ethics Committee of Fujian Medical University Union Hospital 2017YW030-02
9 Ethics Committee of The First Affiliated Hospital of Nanchang University (2017) Lin Lun Shen No.038
10 Ethics Committee of Jinhua Municipal Central Hospital 2017-ethics approval number 003
11 Ethics Committee of Peking University International Hospital D2017-002
12 Ethics Committee of Quanzhou First Hospital, Fujian Quan Yilun [2017] No. 12
13 Ethics Committee of The First Hospital of Jiaxing (2017) ethics approval number 001
14 Ethics Committee of The Third Hospital of Shijiazhuang (2017) ethics approval number 002
15 Ethics Committee of Fujian Provincial Hospital 2017-004-01
16 Ethics Committee of Handan First Hospital IEC-C-006-V1.0
17 Ethics Committee of Lishui City People’s Hospital Lun Shen drug trial (2017-008-01) number
Table S2: The underlying causes of CKD
Cause of CKD N (%)
Diabetic Nephropathy 168 (19.4%)
Hypertension and ischemic renal injury 283 (32.6%)
Primary chronic glomerulonephritis 323 (37.2%)
Secondary glomerulonephritis 34 (3.9%)
Renal tubulointerstitial lesions 10 (1.2%)
Cystic kidney disease 19 (2.2%)
Obstructive nephropathy 3 (0.3%)
Others 28 (3.2%)
ANCA associated systematic Vasculitis 1 (0.1%)
HUS 1 (0.1%)
HbeAg positive chronic viral hepatitis B 1 (0.1%)
IgA nephropathy 2 (0.2%)
Renal biopsy was performed to determine the pathological type 1 (0.1%)
Proteinuria 1 (0.1%)
Amyloidosis 1 (0.1%)
Polycystic kidney 1 (0.1%)
Malignant renal arteriolosclerosis 1 (0.1%)
Hyperuricemia 1 (0.1%)
High blood pressure and gout may cause kidney disease 1 (0.1%)
Hypertensive renal impairment 1 (0.1%)
Capillary proliferative lupus nephritis 1 (0.1%)
Membranous nephropathy 1 (0.1%)
Ischemic renal damage 1 (0.1%)
Nephrotic syndrome 1 (0.1%)
Renal artery stenosis 1 (0.1%)
Unknown 8 (0.9%)
Drugs cause kidney damage 1 (0.1%)
Primary glomerulonephritis and Alport syndrome 1 (0.1%)
Total 868 (100.0%)
N (miss) 3
ANCA, anti-neutrophil cytoplasmic antibody; CKD, chronic kidney disease; HbeAg, hepatitis B e antigen; HUS, hemolytic uremic syndrome; IgA, immunoglobulin A
Table S3: Change in office SBP and DBP from baseline to week 12 in CKD stage subgroups.
CKD Stages Visits N (N miss) SBP (mm Hg; mean [SD]) Change in SBP (mean
[SD]) DBP (mm Hg; mean
[SD]) Change in DBP
(mean [SD])
Stage 1 (N = 129) Baseline 128 (1) 160.4 (14.0) 96.6 (8.8)
Week 4 116 (13) 143.2 (14.3) -17.3 (16.4) 86.0 (10.0) -10.7 (10.1)
Week 8 106 (23) 140.6 (11.5) -19.9 (16.2) 84.6 (8.9) -12.1 (10.5)
Week 12 127 (2) 136.9 (9.9) -23.6 (15.2) 82.9 (7.1) -13.7 (10.0)
Week 12 sensitivity
analysis 129 (0) 136.8 (9.8) -23.5 (15.1) 82.9 (7.1) -13.6 (10.0)
Stage 2 (N = 133) Baseline 132 (1) 163.3 (17.6) 97.3 (12.4)
Week 4 122 (11) 142.7 (13.8) -20.7 (18.2) 85.9 (9.3) -11.3 (12.4)
Week 8 112 (21) 140.0 (12.1) -22.6 (15.9) 84.1 (8.9) -12.7 (11.6)
Week 12 133 (0) 137.2 (12.5) -26.0 (18.5) 83.1 (8.7) -14.1 (12.7)
Week 12 sensitivity analysis
133 (0) 137.2 (12.5) -26.0 (18.5) 83.1(8.7) -14.1 (12.7)
Stage 3 (N = 198) Baseline 198 (0) 163.1 (15.9) 97.7 (12.5)
Week 4 178 (20) 144.2 (15.1) -17.7 (15.7) 84.9(9.2) -11.4 (11.3)
Week 8 161 (37) 141.8 (13.9) -20.1 (16.0) 83.1 (8.4) -13.4 (12.1)
Week 12 197 (1) 139.0 (13.2) -24.2 (16.7) 82.6 (9.7) -15.0 (13.4)
Week 12 sensitivity analysis
198 (0) 139.0 (13.2) -24.2 (16.6) 82.6 (9.6) -15.1 (13.4)
Stage 4 (N = 154) Baseline 153 (1) 164.3 (15.2) 96.9 (11.4)
Week 4 138 (16) 147.7 (15.4) -16.7 (18.1) 86.1 (10.3) -11.1 (11.7)
Week 8 119 (35) 145.0 (14.8) -20.0 (18.4) 84.3 (10.0) -12.9 (11.8)
Week 12 153 (1) 142.1 (13.5) -22.3 (17.1) 83.2 (9.3) -13.7 (10.7)
Week 12 sensitivity
analysis 154 (0) 142.1 (13.5) -22.2 (17.1) 83.2 (9.3) -13.7 (10.6)
DBP, diastolic blood pressure; EFF, efficacy analysis set; N, number of patients with available data; N (miss), number of patients with missing data; SBP, systolic blood pressure; SD, standard deviation
Table S4: SBP and DBP control rate (EFF)
Visits Achieved BP control goal EFF (N = 622)
Week4 Yes 184 (29.6%)
No 377 (60.6%)
Missing 61 (9.8%)
Total 622 (100.0%)
Control rate and 95%CI 32.8% (28.9%,36.7%)
Week8 Yes 207 (33.3%)
No 298 (47.9%)
Missing 117 (18.8%)
Total 622 (100.0%)
Control rate and 95%CI 41.0% (36.7%,45.3%)
Week12 Yes 309 (49.7%)
No 309 (49.7%)
Missing 4 (0.6%)
Total 622 (100.0%)
Control rate and 95%CI 50.0% (46.1%,53.9%) Week12 (sensitivity
analyses) Yes 313 (50.3%)
No 309 (49.7%)
Total 622 (100.0%)
Control rate and 95%CI 50.3% (46.3%,54.3%) DBP, diastolic blood pressure, EFF, efficacy analysis set, SBP, systolic blood pressure
Table S5: Summary of AEs (SAF)
SAF (N=871)
Types Events N (%)
AE 117 72 (8.3%)
ADR 23 23 (2.6%)
AE leading to study discontinuation 20 19 (2.2%)
AE leading to death 0 0 (0.0%)
TEAE 117 72 (8.3%)
Treatment-emergent ADR 23 23 (2.6%)
TEAE leading to drug adjustment 6 6 (0.7%)
TEAE leading to drug interruption 20 19 (2.2%)
SAE 16 15 (1.7%)
Drug related SAE 1 1 (0.1%)
Treatment-emergent SAE 16 15 (1.7%)
Treatment-emergent drug-related SAE 1 1 (0.1%)
Footnote: Denominator of percentage is the No. of SAF patients. AE, adverse events, ADR, adverse drug reactions, SAE, serious adverse events, SAF, safety analysis set, TEAE, treatment-emergent adverse events.
Table S6: Adverse drug reactions (SAF)
Event Type Events N (%)
Adverse Drug Reactions 23 23 (2.6%)
Nervous system disorders 10 10 (1.1%)
Dizziness 7 7 (0.8%)
Headache 3 3 (0.3%)
General disorders and administration site conditions 5 5 (0.6%)
Generalized edema 5 5 (0.6%)
Metabolism and nutrition disorders 1 1 (0.1%)
Hyperkalemia 1 1 (0.1%)
Investigations 1 1 (0.1%)
Increase in heart rate 1 1 (0.1%)
Injury, poisoning and procedural complications 1 1 (0.1%)
Off-label use 1 1 (0.1%)
Musculoskeletal and connective tissue disorders 1 1 (0.1%)
Backache 1 1 (0.1%)
Respiratory, thoracic, and mediastinal diseases 1 1 (0.1%)
Cough 1 1 (0.1%)
Gastrointestinal disorders 1 1 (0.1%)
Diarrhea 1 1 (0.1%)
Cardiac disorders 1 1 (0.1%)
Palpitation 1 1 (0.1%)
Vascular disorders 1 1 (0.1%)
Flushing 1 1 (0.1%)
Footnote: Denominator of percentage is the No. of SAF patients. SAF, safety analysis set
Table S7: Serious adverse events (SAF)
Serious Adverse Events 16 15 (1.7%)
Renal and urinary disorders 6 6 (0.7%)
Chronic kidney disease 5 5 (0.6%)
Nephrotic syndrome 1 1 (0.1%)
Infections and infestations 4 3 (0.3%)
Pulmonary mycosis 1 1 (0.1%)
Pneumonia 1 1 (0.1%)
Appendicitis 1 1 (0.1%)
Pneumonia bacterial 1 1 (0.1%)
Metabolism and nutrition disorders 2 2 (0.2%)
Hyperkalemia 2 2 (0.2%)
Investigations 1 1 (0.1%)
Blood pressure increased 1 1 (0.1%)
Nervous system disorders 1 1 (0.1%)
Cerebral hemorrhage 1 1 (0.1%)
Gastrointestinal disorders 1 1 (0.1%)
Rectal polyp 1 1 (0.1%)
Cardiac disorders 1 1 (0.1%)
Cardiac failure 1 1 (0.1%)
Footnote: Denominator of percentage is the No. of SAF patients. SAF, safety analysis set